Financial Assessment Before And After Acquisition Of Pharmeasy And Thyrocare (FY 2020–23)

Dr. Apurva Yashwante[1], Dr. Asha Saxena[2]

[1]Assistant Professor, Commerce & Management, SAM College, Bhopal.
[2]Principal, SAM College, Bhopal.

Abstract

This research paper aims to evaluate the financial implications of the acquisition of Thyrocare Technologies by PharmEasy, a landmark deal in the Indian healthcare and diagnostics sector. The study assesses key financial indicators such as revenue growth, profitability, debt ratios, and operational efficiency before and after the acquisition. By analyzing financial reports, industry trends, and strategic moves, the paper offers insights into how the acquisition impacted the financial stability and growth trajectory of both entities. The findings highlight the challenges and synergies involved in the deal and provide a basis for understanding mergers in the Indian healthcare ecosystem.

Keywords: financial assessment, acquisition, revenue growth

Introduction

In June 2021, API Holdings, the parent company of PharmEasy, acquired a 66.1% stake in Thyrocare Technologies for approximately Rs. 4,546 crore. This deal was the first major instance in India where a digital healthcare platform acquired a traditional diagnostics chain, symbolizing the evolving landscape of the healthcare sector. The acquisition was driven by a vision to build an integrated digital healthcare ecosystem encompassing pharmacy, diagnostics, and telemedicine.

Thyrocare, established in 1996, is one of India's leading diagnostics chains with a strong brand reputation, while PharmEasy, founded in 2015, is a digital health startup that provides online medicine delivery and healthcare services. This research assesses the financial performance of both companies before and after the acquisition to determine whether the merger achieved its intended strategic and financial objectives.

Objectives

The primary objectives of this study are:

1. To analyze the financial health of PharmEasy and Thyrocare before the acquisition.
2. To evaluate the financial performance of the combined entity post-acquisition.
3. To identify the key synergies and challenges encountered due to the acquisition.
4. To assess whether the acquisition improved shareholder value and operational efficiency.
5. To draw conclusions and offer recommendations for future mergers in the healthcare sector.

Review of Literature

Numerous studies have been conducted on mergers and acquisitions (M&As), highlighting their impact on financial performance, market share, and shareholder wealth. According to Ghosh and Jain (2000), mergers often lead to improved financial metrics in the long run, though initial integration may cause volatility. Kumar and Bansal (2008) emphasize the role of due diligence and strategic fit in determining acquisition success.

In the healthcare sector, Gupta (2019) observed that digital consolidation enhances customer reach and cost efficiency. Literature also suggests that acquisitions between digital and traditional players create unique integration challenges, especially in managing workforce, technology, and service delivery (Reddy &Rao, 2021).

The acquisition of Thyrocare by PharmEasy marked a significant event in the Indian healthcare and diagnostics sector. Several studies and industry analyses have explored the broader implications of mergers and acquisitions (M&A) in the healthcare space, especially in the context of vertical integration. This section compiles various research findings relevant to the financial and strategic impacts of such acquisitions.

Study by Ghosh and Dutta (2020)

Ghosh and Dutta examined financial synergies in healthcare sector acquisitions in India and concluded that **vertical acquisitions often lead to short-term diseconomies of scale** due to integration costs and operational misalignment. However, the long-term prospects remain positive if the integration is managed efficiently. Their analysis covered companies like Fortis Healthcare and Medanta, providing a foundational understanding of how vertical integration in Indian healthcare affects financial outcomes.

Research by Kapoor (2019)

Kapoor investigated the impact of acquisitions on the financial health of e-health startups in India. He found that most startups experienced **revenue growth post-acquisition** but also faced increased operational losses due to rapid scaling, marketing expenditure, and technology investments. The study emphasized that acquisitions must be complemented with sound cost management strategies to realize profitability.

EY Report on Indian Healthcare (2021)

According to a report by Ernst & Young titled *"Reshaping the Indian Healthcare Ecosystem"*, digital health platforms have accelerated post-pandemic, and acquisitions like that of Thyrocare by PharmEasy represent strategic attempts to **combine diagnostics, teleconsultation, and e-pharmacy into a single ecosystem**. However, the report warns of integration challenges, particularly in harmonizing company cultures, workflows, and data systems.

Bansal&Rao (2018)

In a study focusing on diagnostic chains in India, Bansal and Rao observed that traditional diagnostic labs (e.g., SRL, Thyrocare) operate on **thin margins but stable cash flows**, whereas digital health platforms operate with **high customer acquisition costs and delayed profitability**. They argued that for such mergers to succeed, financial discipline and shared goal-setting must be prioritized over rapid expansion.

KPMG India Healthcare Analysis (2022)

KPMG's analysis post-PharmEasy's acquisition pointed out that **despite the theoretical benefits of vertical integration**, execution remains the primary challenge. Their findings revealed that startups often face difficulty in managing acquired legacy systems and maintaining brand equity, especially in regulated sectors like healthcare and diagnostics.

Verma & Shukla (2022)

This study specifically analyzed the PharmEasy-Thyrocare deal, suggesting that the acquisition was a **first-of-its-kind reverse acquisition** where a tech startup acquired a profitable traditional company. The authors argued that PharmEasy's move was strategic for market expansion but financially risky due to the bridge loan and lack of immediate profit realization. They noted that Thyrocare's revenue dipped post-acquisition, indicating integration inefficiencies.

Research Methodology

Research Design: Descriptive and analytical.
Data Sources: Secondary data from financial statements, annual reports, news articles, and financial databases.
Tools and Techniques: Ratio analysis, comparative analysis, and trend analysis.
Scope: The study focuses on PharmEasy (API Holdings) and Thyrocare Technologies Ltd.

Analysis & Interpretation

Revenue Comparison Before and After Acquisition Debt-to-Equity Ratio Comparison Before and After





This section analyzes and interprets key financial indicators of PharmEasy and Thyrocare during the period **before FY2020–21** and **after FY2022–23** the acquisition. The aim is to assess whether the acquisition resulted in financial gains, improved market positioning, or efficiency in operations.

A. Financial Analysis of PharmEasy

1. Revenue Growth

Year	Revenue (Crore)
FY 2020–21	737
FY 2021–22	2,335
FY 2022–23	6,644

Interpretation:
PharmEasy's revenue grew nearly **9x** over three years, reflecting aggressive expansion and customer acquisition. A major jump occurred post-acquisition, showing the company leveraged Thyrocare's diagnostic network to offer bundled services (consultation + diagnostics + medicines).
Chart: Revenue Trend of PharmEasy (FY21–FY23)

2. Net Loss

Year	Net Loss (Crore)
FY 2020–21	100
FY 2021–22	641
FY 2022–23	5,210

Interpretation:
Despite revenue growth, PharmEasy's losses widened sharply, due to:
- High marketing and tech costs
- Acquisition-related interest burden
- Expansion into Tier-II and Tier-III cities
- Amortization of intangible assets post-acquisition

3. Debt-to-Equity Ratio

Year	D/E Ratio
FY 2020–21	0.2
FY 2021–22	1.3
FY 2022–23	2.7

Interpretation:
The D/E ratio rose significantly, indicating **heavy dependence on debt**, particularly from the ₹4,546 crore bridge loan raised to acquire Thyrocare.

B. Financial Analysis of Thyrocare
1. Revenue Performance

Year	Revenue (Crore)
FY 2020–21	474
FY 2021–22	497
FY 2022–23	452

Interpretation:
Thyrocare's revenue **stagnated and slightly declined** post-acquisition. This could be due to:
- Integration challenges
- Branding overshadowed by PharmEasy
- Loss of autonomy and delayed alignment of goals

2. Net Profit

Year	Net Profit (Crore)
FY 2020–21	111
FY 2021–22	76
FY 2022–23	46

Interpretation:
Thyrocare's profits **declined consistently**, indicating potential inefficiencies in the post-acquisition phase and a possible mismatch of operating models.

3. Debt-to-Equity Ratio

Year	D/E Ratio
FY 2020–21	0.1
FY 2021–22	0.5
FY 2022–23	1.1

Interpretation:
Debt increased post-acquisition, despite Thyrocare previously being a low-debt, high-cash-flow company.

Overall Interpretation

- **Synergies Not Fully Realized:** Despite vertical integration (e-commerce + diagnostics), expected synergies (cost savings, better reach) did not reflect in Thyrocare's performance.
- **PharmEasy Scaling with High Risk:** The acquisition helped PharmEasy expand into diagnostics quickly, but the cost was high—reflected in poor profitability and a rising debt burden.
- **Cultural and Operational Mismatch:** A digitally aggressive, startup-style PharmEasy integrating a traditional diagnostics lab chain like Thyrocare likely faced cultural friction.
- **Debt Pressure:** The bridge loan added enormous financial stress, affecting PharmEasy's ability to turn profitable, leading to their deferred IPO plans.

Conclusions

1. **Financial Performance**:
   - PharmEasy saw exponential **top-line growth**, but **bottom-line erosion** due to over-leverage and high costs.
   - Thyrocare, instead of gaining scale and digital benefits, **lost momentum** and profit margins declined.
2. **Strategic Outcome**:
   - The acquisition appears **strategically sound but poorly executed**.
   - Lack of effective integration and synergy realization is evident.
3. **Investor Implication**:
   - PharmEasy's rising losses make it less attractive to investors unless it restructures operations.
   - Thyrocare may face declining valuation if not revived through strategic restructuring.
4. **Market Insight**:

- The case shows how **vertical integration in healthcare** requires robust execution and alignment, not just funding and vision.

Recommendations

- **Restructure Debt:** Convert bridge loans to long-term capital or equity to ease financial stress.
- **Brand Clarity:** Avoid overshadowing Thyrocare's brand with PharmEasy's presence.
- **Synergy Mapping:** Realign operations for better data integration, bundled offerings, and resource sharing.
- **Cost Rationalization:** Trim down non-core spending and re-focus on operational excellence.

References

1. Bansal, R., & Rao, P. (2018). *An analysis of diagnostic healthcare chains in India: Challenges and growth opportunities*. Indian Journal of Healthcare Management, 12(3), 45–53.
2. EY India. (2021). *Reshaping the Indian Healthcare Ecosystem*. Ernst & Young Global Limited. Retrieved from: https://www.ey.com/en_in
3. Ghosh, S., & Dutta, R. (2020). Financial Synergies in Healthcare Sector M\&A: A Case Study Approach. *International Journal of Financial Research*, 11(5), 202–210. https://doi.org/10.5430/ijfr.v11n5p202
4. Kapoor, A. (2019). Startup Acquisitions and Financial Outcomes: The Indian Health-Tech Story. *Journal of Entrepreneurship and Innovation in Emerging Economies*, 5(2), 167–184.
5. KPMG India. (2022). *Healthcare and Pharma Outlook: Structural Shifts and Opportunities*. Retrieved from: https://home.kpmg/in/en/home/industries/healthcare.html
6. LocalCircles. (2023). *Healthcare Services Post-Acquisition: Consumer Survey*. Retrieved from: https://www.localcircles.com/
7. McKinsey & Company. (2021). *M\&A in Healthcare: Strategic Value Creation*. Retrieved from: https://www.mckinsey.com/industries/healthcare
8. NASSCOM. (2023). *India Startups Report: HealthTech Sector and Strategic M\&As*. Retrieved from: https://nasscom.in/
9. Pandey, R., & Mittal, S. (2020). Impact of Mergers and Acquisitions on Financial Performance: Evidence from Indian Service Sector. *Journal of Accounting and Business Research*, 8(1), 61–75.
10. Verma, N., & Shukla, K. (2022). PharmEasy's Acquisition of Thyrocare: A Reverse Acquisition Case Study. *Asia-Pacific Journal of Management and Innovation*, 3(4), 99–112.